Clinical trials: Thalidomide
Myelodysplastic Syndrome
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
This is a Phase II, open-label, non-randomized study in patients with low, intermediate-1, intermediate-2, or high-risk MDS (defined by IPSS). Each cycle of treatment will be 6 weeks in length.
- Trial name
- NCT00251511
- Testing
- Arsenic Trioxide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Veeda Oncology
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Crohn Disease
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.
- Trial name
- FMT (NCT05321758)
- Testing
- Fecal Microbiota Transplantation, Immunosuppressive Agents
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Chemotherapy-induced Peripheral Neuropathy, Quality of Life
International CIPN Assessment and Validation Study
This is an observational study of chemotherapy-induced peripheral neurotoxicity (CIPN) patients to be investigated prospectively in order to assess responsiveness of a set of outcome measures in an international multi-center…
- Trial name
- ICAVS (NCT04633655)
- Testing
- outcome measures for CIPN testing
- Where
- 30 sites in United States, Australia and 14 more
- Volunteers
- 1,000 people
- Sponsor
- University of Milano Bicocca
Fetal Hemoglobin, Beta-Thalassemia
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
The project, titled "Long Term Beta Thalassemia Treatment: Findings From The Extension Period Of Phase 2 Clinical Trial," aims to compare the efficacy and safety of combination therapy (thalidomide and hydroxyurea) versus…
- Conditions
- Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies
- Trial name
- Thalidomide (NCT06490601)
- Testing
- thalidomide and hydroxyurea, Thalidomide
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Multiple Myeloma
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib)…
- Trial name
- IFM2013-04 (NCT01971658)
- Testing
- Thalidomide®, Cyclophosphamide, Velcade®
- Where
- 62 sites in France
- Volunteers
- 358 people
- Sponsor
- Nantes University Hospital
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed chronic lymphocytic leukemia. Thalidomide may stop the growth of chronic lymphocytic leukemia by stopping blood flow to the tumor.
- Trial name
- NCT00006226
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114192
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Multiple Myeloma
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
- Trial name
- NCT00057564
- Testing
- A (Thalidomide + Dexamethasone)
- Where
- 99 sites in United States, Australia and 14 more
- Volunteers
- 470 people
- Sponsor
- Celgene Corporation
Kidney Cancer
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Interferon alfa-2b may interfere with the growth of the cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00005966
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Melanoma (Skin)
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00026520
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 94 sites in United States
- Sponsor
- SWOG Cancer Research Network
COVID-19 Thalidomide
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19
In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment.
- Trial name
- NCT04273581
- Testing
- Thalidomide
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to…
- Trial name
- NCT00458705
- Testing
- bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
Study Objectives 1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide (Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or refractory multiple myeloma (MM) who…
- Trial name
- DexTR (NCT00538824)
- Testing
- dexamethasone, thalidomide, lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma, Small Intestine Cancer
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031941
- Testing
- lenalidomide
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
To investigate the efficacy of a modified bortezomib based combination therapy for patients with multiple myeloma.
- Trial name
- NCT02559154
- Testing
- Bortezomib, Dexamethasone, Doxorubicin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Discoid Lupus Erythematosus
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing.
- Trial name
- NCT00001680
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
The proposed study will evaluate whether the combination of VELCADE, Thalidomide , Melphalan and Prednisone (V-MPT), as induction treatment for newly diagnosed elderly MM patients, improves outcomes compared to the combination…
- Trial name
- NCT01063179
- Testing
- Bortezomib, Melphalan, Prednisone, Thalidomide, Bortezomib, Melphalan, Prednisone
- Where
- Italy
- Volunteers
- 511 people
- Sponsor
- Fondazione EMN Italy Onlus
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Conditions
- Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00020046
- Testing
- docetaxel, thalidomide
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections, HIV Wasting Syndrome
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of thalidomide in reducing weight loss in patients with HIV wasting syndrome.
- Trial name
- NCT00002127
- Testing
- Thalidomide
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Celgene Corporation